



## CORRIGENDUM

In continuation to the corrigendum issued vide No: JKMSCL/GM(Drugs)/Corg/653/2025/957-96, dated 24-03-2025 under e-NIT ref No: **JKMSCL/DRUGS & MEDICINES/ 2025-2026/653 DATED: 22-02-2025** for the procurement of Allopathic Drugs. The following amendments are made in continuation and are as under:

S.No	Instead of	Please read as
1.	Inj. Anti Snake Venum Anti Serum Lypholized (Polyvalent Anti Snake Venum) 10ml, 10 ml vial [EDL-641]	<b>Deleted</b>
2.	Inj. Meropenam 500mg, Vial[EDL-1006B]	<b>Deleted</b>
3	Surfactant for Intratracheal 4ml vial [EDL-1459C]	<b>Deleted</b>
4	Erythropoietin 10000PFS[EDL-2051]	<b>Deleted</b>
5	Iopromide Injection 62% w/v, 300mg/ml, [EDL-2139B]	<b>Deleted</b>
6	Sodium Chloride 0.9% isotonic 500ml pack [EDL-1400]	<b>Deleted</b>
7	Inj. Methylene Blue 10mg/ML, 10ml Vial [979A]	Inj. Methylene Blue 10mg/ML, 10ml <b>Ampule</b> [979A]
8	Anti- Inhibitor coagulation complex [Human plasma protein with a factor VIII Inhibitor bypassing activity]: 500 IU per vial with 20ml solvent per vial [EDL-2134]	Anti- Inhibitor coagulation complex [Human plasma protein with a factor VIII Inhibitor bypassing activity]: <b>500 U</b> per vial with <b>10ml</b> solvent
9	Budesonide Inhalation MDI DPI 100mcg dose 120ml pack [EDL-2104]	Budesonide Inhalation MDI DPI 100mcg dose <b>200 MDI pack</b> [EDL-2104]
10	Budesonide(A)+ Formoterol (B) Inhalation 100mcg(A)+6mcg(B)/dose 120ml pack, 160 mcg+4.5 mcg [EDL-1392]	Budesonide(A)+ Formoterol (B) Inhalation 100mcg(A)+6mcg(B)/dose <b>120 MDI pack</b> , 160 mcg+4.5 mcg [EDL-1392]
11	Levosambutamol Inhalation MDI DPI 100mcg dose 120ml pack (Inhaler/Rotacaps) EDL-1181	Levosambutamol Inhalation MDI DPI 100mcg dose <b>120 MDI pack</b> (Inhaler/Rotacaps) [EDL-1181]
12	Mefanamic Acid 20mg, 1x10 cap/tab EDL-100	Mefanamic Acid 20mg, 1x10 cap/tab [EDL-100] <b>Per Tab/Cap</b>
13	Morphine Sulphate 2mg/ml PFS	Morphine Sulphate 2mg/ml

*JKMSCL*




		<b>Per PFS</b>
14	Butorphanol Tartarate 2mg/ml, 1ml ampoule EDL-2011	Butorphanol Tartarate 2mg/ml, 1ml Ampoule EDL-2011 <b>Per Ampule</b>
15	Ceftriaxone injection I.P. 500gm, vial EDL-2033	Ceftriaxone injection I.P. <b>500mg</b> , vial [EDL-2033]
16	Bupropion 150mg, 1x10 tab EDL-2095	Bupropion 150mg, 1x10 tab [EDL-2095] <b>Per Tab</b>
17	Calcium carbonate Each 100ml contains:sodium chloride 600mg potassium chloride 40mg calcium chloride 0.24mg,sodium lectate 0.312mg 500ml FFS bottle EDL-ED003	Calcium carbonate Each 100ml contains:sodium chloride 600mg potassium chloride 40mg calcium chloride 0.24mg,sodium lectate 0.312mg 500ml FFS bottle [EDL-ED003] <b>Per FFS bottle</b>
18	Rifampicin 150mg, 1x10 tab strip EDL-2109	Rifampicin 150mg, 1x10 tab strip [EDL-2109] <b>Per Tab</b>
19	Rifampicin 100mg, 1x10 tab strip EDL-2110	Rifampicin 100mg, 1x10 tab strip [EDL-2110] <b>Per Tab</b>
20	Clofazimine 50mg, 1x10 tab strip EDL-2115	Clofazimine 50mg, 1x10 tab strip [EDL-2115] Per T.ab
21	Planosterone 0.5mg/5ml tab pack EDL-2132	Planosterone 0.5mg/5ml vial [EDL-2132] <b>Per Vial</b>

**Further more critical dates are hereby extended as follows:**

<b>Last date of submission of bid documents</b>	<b>22-04-2025 upto 16.00 hrs</b>
<b>Opening of technical bid</b>	<b>24-04-2025 at 11.00 hrs</b>

All other Terms & conditions of the said NIT shall remain the same.

  
General Manager (Drugs)  
JKMSCL

No: JKMSCL/GM (Drugs)/Corg-653/2025/26-30

Dated: 04-04-2025.

Copy for information to the :-

1. Managing Director, JKMSCL
2. Financial Advisor/CAO, JKMSCL
3. General Manager(Adm), JKMSCL
4. Deputy General Manager (IT Cell), JKMSCL
5. AP(M), JKMSCL to upload the corrigendum on the official website.
6. Office file